key papersKey paper
International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)
A parallel classification to the WHO 2022 edition from an international expert group, which among other changes creates an MDS/AML category for 10 to 19 percent blasts and gives TP53-mutated disease its own entities.
Overview
Classification of myeloid neoplasms and acute leukaemias integrating morphology, clinical features and genomics, produced by the International Consensus Classification group, with new categories for MDS/AML, TP53-mutated myeloid neoplasms and genetically defined AML subtypes at lower blast thresholds.
GuidelineChanged practice
Authors
Arber DA, Orazi A, Hasserjian RP, et al.
Published
Blood, 2022
What it means
Trial eligibility and risk stratification in AML and MDS often refer to this classification alongside the WHO edition; the two overlap heavily but not completely.
Caveats
- Coexists with the WHO fifth edition, so the same marrow may carry two names.